252 related articles for article (PubMed ID: 15931645)
21. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
22. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
23. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
24. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
25. Oral iron absorption in hemodialysis patients treated with erythropoietin.
Donnelly SM; Posen GA; Ali MA
Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
[TBL] [Abstract][Full Text] [Related]
26. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
[TBL] [Abstract][Full Text] [Related]
27. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
[TBL] [Abstract][Full Text] [Related]
28. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid hormone contributes to variations in blood morphology in diabetic and non diabetic patients treated with continuous ambulatory peritoneal dialysis.
Grzegorzewska AE; Mariak I
Adv Perit Dial; 2001; 17():5-9. PubMed ID: 11510296
[TBL] [Abstract][Full Text] [Related]
30. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
Sahin S; Sahin GM; Ergin H; Kantarci G
Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
[TBL] [Abstract][Full Text] [Related]
31. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
32. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
Sirover WD; Siddiqui AA; Benz RL
Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
[TBL] [Abstract][Full Text] [Related]
33. Staff-assisted nursing home haemodialysis: patient characteristics and outcomes.
Reddy NC; Korbet SM; Wozniak JA; Floramo SL; Lewis EJ
Nephrol Dial Transplant; 2007 May; 22(5):1399-406. PubMed ID: 17259652
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight.
Tovbin D; Markowitz A; Mostoslavsky M; Landver R
Clin Nephrol; 2000 Apr; 53(4):276-82. PubMed ID: 10809415
[TBL] [Abstract][Full Text] [Related]
35. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
[TBL] [Abstract][Full Text] [Related]
36. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
37. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
Rangel EB; Espósito BP; Carneiro FD; Mallet AC; Matos AC; Andreoli MC; Guimarães-Souza NK; Santos BF
Ther Apher Dial; 2010 Apr; 14(2):186-92. PubMed ID: 20438541
[TBL] [Abstract][Full Text] [Related]
38. Time trends in the epidemiology of renal transplant patients with type 1 diabetes mellitus over the last four decades.
Cao C; Hellermann JP; Weber M; Ambühl PM
Nephrol Dial Transplant; 2006 Mar; 21(3):770-5. PubMed ID: 16401627
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients.
Sit D; Kadiroglu AK; Yilmaz ME; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):403-7. PubMed ID: 16060127
[TBL] [Abstract][Full Text] [Related]
40. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
